Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 5/20 | 0.74 |
| ▸ | RAB9A | P51151 | 5/20 | 0.74 |
| ▸ | MEN1 | O00255 | 3/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.74 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.74 |
| ▸ | NR1H4 | Q96RI1 | 2/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.61 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.60 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.60 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.59 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.58 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.58 |
| ▸ | MITF | O75030 | 1/20 | 0.58 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.57 |
| ▸ | TP53 | P04637 | 1/20 | 0.57 |
| ▸ | FABP1 | P07148 | 1/20 | 0.57 |
| ▸ | TRPV1 | Q8NER1 | 1/20 | 0.56 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4186005 | 0.91 | SMN1; SMN2 (0.71) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4171948 | 0.89 | CYP2C8 (0.69) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL13639753 | 0.84 | RXFP1 (0.62) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23070447 | 0.84 | RAB9A (0.81) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL2907086 | 0.83 | HSP90AA1 (0.65) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL23070455 | 0.81 | KCNK9 (0.83) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4165226 | 0.80 | SELL (0.69) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL4174870 | 0.80 | CYP1A2 (0.67) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL6300804 | 0.80 | POLB (0.67) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL7828529 | 0.80 | RAB9A (0.75) | NPC1RAB9AMEN1KMT2ASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| EP-1948146-B1 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2012-11-07 | — | — | EP | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2009-01-29 | — | — | US | disclosed |
| EP-1948146-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | Revotar Biopharmaceuticals AG (DE) | 2008-07-30 | — | — | EP | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
| WO-2007039111-A2 | NOVEL MULTI-CYCLIC COMPOUNDS AND THEIR USE | REVOTAR BIOPHARMACEUTICALS AG (DE) | 2007-04-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090030015-A1 | NOVEL MULTI-CYCLIC COMPOUNDS | SELP, SELE, SELL | NPC1 1102/4885RAB9A 2400/4885MEN1 3851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.